Try our beta test site

Study of MLN8237 in Patients With Advanced Hematological Malignancies

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. ) Identifier:
First received: June 11, 2008
Last updated: September 22, 2016
Last verified: September 2016
This is an open-label, multicenter, phase 1 study of MLN8237 in subjects with advanced hematological malignancies for whom there are limited standard treatment options.

Condition Intervention Phase
B-cell Follicular Lymphoma
B-cell Marginal Zone Lymphoma
Diffuse Large B-cell Lymphoma
B-cell Mantle Cell Lymphoma
B-cell Small Lymphocytic Lymphoma (SLL)
B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Multiple Myeloma
Waldenstrom's Macroglobulinemia
Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS)
Angioimmunoblastic T-cell Lymphoma (AITL)
Anaplastic Large Cell Lymphoma
Enteropathy Associated T-cell Lymphoma (EATCL)
NK Lymphoma (NKL)
Drug: MLN8237
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Determine dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of orally administered MLN8237; and to evaluate the pharmacokinetics of MLN8237. [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • To determine if MLN8237 has antitumor activity as measured by tumor response. [ Time Frame: Evaluations will be repeated after every 2 cycles of MLN8237 have been completed for up to 12 months ]
  • To evaluate the potential effect of MLN8237 exposure on Aurora A kinase inhibition in blood leukocytes [ Time Frame: Before and during the first cycle of treatment ]

Enrollment: 58
Study Start Date: July 2008
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: MLN8237

MLN8237 administered twice daily (BID) on Days 1-7 of each cycle. The planned rest period is 14 days in length.

Number of Cycles: until progression or unacceptable toxicity, up to 12 months unless clinical benefit supports continued therapy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed or refractory disease and a histologically or cytologically confirmed hematological malignancy of the following type for which standard curative treatment does not exist or is no longer effective:

    • B-cell Follicular lymphoma
    • B-cell Marginal zone lymphoma
    • Diffuse large B-cell lymphoma
    • B-cell Mantle cell lymphoma
    • B-cell Small lymphocytic lymphoma (SLL)
    • B-Cell Chronic lymphocytic leukemia (B-CLL)
    • Multiple myeloma
    • Waldenstrom's macroglobulinemia
    • Noncutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
    • Angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma, enteropathy associated T-cell lymphoma (EATCL), NK lymphoma (NKL)
  • Subjects with diffuse large B-cell lymphoma must have failed, be ineligible for, or have refused an autologous stem cell transplant. There is no restriction regarding the maximum number of prior regimens.
  • Aged 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Radiographically or clinically evaluable disease for Part 1 of this study and measurable disease for Part 2 of this study
  • Suitable venous access for the conduct of blood sampling for MLN8237 PK
  • Recovered from the reversible effects of prior antineoplastic treatment (with the exception of alopecia and Grade 1 neuropathy)

Exclusion Criteria:

  • Pregnant or lactating
  • Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 as specified in the protocol
  • Prior allogeneic bone marrow (or other organ) transplantation
  • Newly diagnosed or uncontrolled cancer-related CNS disease
  • Systemic antineoplastic treatment within 21 days preceding the first dose of study treatment. Exceptions requiring a 42-day recovery period from last treatment include: Nitrosoureas, mitomycin C or Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody (21 days if clear evidence of progressive disease)
  • Treatment with radioimmunoconjugates or toxin immunoconjugates such as ibritumomab tiuxetan (Zevalin™), or tositumomab (Bexxar®) within 56 days preceding the first dose of study treatment
  • Antineoplastic treatment with glucocorticoids within 21 days preceding the first dose of study treatment
  • Radiotherapy involving <25% of the hematopoietically active bone marrow within 21 days preceding first dose of study treatment
  • Radiotherapy involving ≥25% of the hematopoietically active bone marrow within 42 days preceding first dose of study treatment
  • Inability to swallow capsules or known GI disease or GI procedures that could interfere with the oral absorption or tolerance of MLN8237. Examples include, but are not limited to, partial gastrectomy, history of small intestine surgery, and celiac disease.
  • History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease
  • Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection. Testing is not required in the absence of clinical findings or suspicion.
  • Patients who fail to meet laboratory values as specified in the protocol during the screening period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00697346

United States, Arizona
Scottsdale, Arizona, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Jersey
Hackensack, New Jersey, United States
United States, New York
Buffalo, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Houston, Texas, United States
San Antonio, Texas, United States
Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Millennium Pharmaceuticals, Inc. Identifier: NCT00697346     History of Changes
Other Study ID Numbers: C14003 
Study First Received: June 11, 2008
Last Updated: September 22, 2016

Additional relevant MeSH terms:
Multiple Myeloma
Lymphoma, Follicular
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, B-Cell, Marginal Zone
Lymphoma, T-Cell
Lymphoma, Large B-Cell, Diffuse
Waldenstrom Macroglobulinemia
Lymphoma, Large-Cell, Anaplastic
Lymphoma, T-Cell, Peripheral
Immunoblastic Lymphadenopathy
Intestinal Diseases
Enteropathy-Associated T-Cell Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders processed this record on February 27, 2017